DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-4.88%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$266M
AUM Growth
+$266M
(-0.05%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
7.19%
Top 10 Holdings %
Top 10 Hldgs %
48.53%
Holding
96
New
9
Increased
25
Reduced
15
Closed
6
Top Buys
| 1 |
Fate Therapeutics
FATE
|
$6.37M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$4.09M |
| 3 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$3.18M |
| 4 |
MacroGenics
MGNX
|
$1.91M |
| 5 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$1.84M |
Top Sells
| 1 |
Quince Therapeutics
QNCX
|
$2.78M |
| 2 |
Indaptus Therapeutics
INDP
|
$1.81M |
| 3 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
$1.53M |
| 4 |
NextCure
NXTC
|
$1.44M |
| 5 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$1.19M |
Sector Composition
| 1 | Healthcare | 92.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$261M
| $48M | 18.06% | 13,680,554 | – | – |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $17.5M | 6.58% | 124,806 +1,000 | +0.8% | +$140K |
|
|
ALDR
3
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $12M | 4.51% | 636,013 | – | – |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $9.05M | 3.4% | 123,218 | – | – |
|
5
Galapagos
GLPG
$2.07B
| $8.02M | 3.01% | 52,509 | – | – |
|
6
AtriCure
ATRC
$1.84B
| $7.95M | 2.99% | 318,729 | – | – |
|
|
7
Fate Therapeutics
FATE
$120M
| $7.3M | 2.75% | 470,000 +409,969 | +683% | +$6.37M |
|
|
TVRD
8
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $6.93M | 2.61% | 378,924 +173,913 | +85% | +$3.18M |
|
9
iShares Biotechnology ETF
IBB
$5.6B
| $6.46M | 2.43% | 64,900 +3,500 | +6% | +$348K |
|
10
Ascendis Pharma
ASND
$11.8B
| $5.83M | 2.19% | 60,480 +1,100 | +2% | +$106K |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $5.81M | 2.19% | 64,508 -100 | -0.2% | -$9.01K |
|
|
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
| $5.72M | 2.15% | 142,764 +2,000 | +1% | +$80.1K |
|
|
AERI
13
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $5.53M | 2.08% | 287,748 +82,308 | +40% | +$1.58M |
|
14
DexCom
DXCM
$29.5B
| $5.42M | 2.04% | 36,338 | – | – |
|
15
Cytokinetics
CYTK
$4.23B
| $4.77M | 1.79% | 418,727 -58,469 | -12% | -$665K |
|
|
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.3M | 1.62% | 93,942 | – | – |
|
|
LMNX
17
DELISTED
Luminex Corp
LMNX
| $4.21M | 1.58% | 204,091 +10,000 | +5% | +$206K |
|
|
18
Apellis Pharmaceuticals
APLS
$3.48B
| $4.09M | 1.54% | +169,800 | New | +$4.09M |
|
19
Wave Life Sciences
WVE
$1.53B
| $4.06M | 1.53% | 197,554 -20,000 | -9% | -$411K |
|
|
BHVN
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.96M | 1.49% | 95,000 | – | – |
|
21
VYNE Therapeutics
VYNE
$8.16M
| $3.84M | 1.44% | 856,936 +256,906 | +43% | +$1.15M |
|
|
ARQL
22
DELISTED
Arqule Inc
ARQL
| $3.8M | 1.43% | 530,262 +32,500 | +7% | +$233K |
|
|
TBIO
23
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $3.61M | 1.36% | 364,229 +185,923 | +104% | +$1.84M |
|
24
Akebia Therapeutics
AKBA
$833M
| $3.25M | 1.22% | 828,038 -2,500 | -0.3% | -$9.8K |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $2.98M | 1.12% | 330,667 | – | – |
|